CORRECTING and REPLACING -- Noodles & Company Announces

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CORRECTING and REPLACING -- Noodles & Company Announces Preliminary Results for Fourth Quarter 2013

BROOMFIELD, Colo., Jan. 13, 2014 (GLOBE NEWSWIRE) -- In a release dated January 13, 2014, the expected increase in comparable restaurant sales information was not correctly presented for the fourth quarter of 2013. Comparable restaurant sales are expected to increase 4.3% for company-owned restaurants, 1.5% for franchised restaurants and 3.9% system-wide for the fourth quarter of 2013 compared to the fourth quarter of 2012.

The corrected release reads:

Noodles & Company Announces Preliminary Results for Fourth Quarter 2013

BROOMFIELD, Colo., January 13, 2014 (Globe Newswire) - In advance of management's attendance at the 16th annual ICR XChange Conference and the Jefferies 3rd Annual Winter Consumer Summit, Noodles & Company (Nasdaq: NDLS ) today announced preliminary unaudited financial results for the fourth quarter ended December 31, 2013.

Highlights of expected results for the fourth quarter of 2013 compared to the fourth quarter of 2012 include:

  • Total revenue expected to increase 17.4% to $91.5 million from $77.9 million
  • Comparable restaurant sales expected to increase 4.3% for company-owned restaurants, 1.5% for franchised restaurants and 3.9% system-wide
  • 12 new restaurants opened system-wide, including eight company-owned and four franchise restaurants

Preliminary fourth quarter 2013 results

Total revenue is expected to increase $13.5 million to $91.5 million in the fourth quarter, up 17.4% over the fourth quarter of 2012 on an expected system-wide comparable restaurant sales increase of 3.9%. Comparable restaurant sales represent year-over-year sales comparisons for restaurants open for at least 18 full periods. The expected results presented in this press release are based on preliminary financial data and are subject to change until the year-end financial reporting process is complete.

The system opened 12 restaurants in the quarter, including eight company and four franchise locations. As of December 31 st , 2013, Noodles & Company operated 318 company-owned locations and 62 franchise locations.

Chairman and CEO Kevin Reddy remarked, "I am very pleased with our team's continued efforts in building a Category of One in the restaurant space. Our strong top line growth in the fourth quarter, despite significant weather headwinds in many of our markets, is evidence of the strength and resiliency of our concept. I am also proud of our company and franchise development teams opening a record number of restaurants in 2013 as we continue in the early stages of our path to 2,500 restaurants nationwide."

Upcoming Events

Noodles & Company's management will present at the 16th Annual ICR XChange Conference at the Grande Lakes Orlando Resort in Florida on January 14, 2014. The presentation will begin at 12:30 PM Eastern time. Investors and interested parties may listen to a webcast of this presentation by visiting www.noodles.com and clicking the tab "Investor Relations" or directly through ICR XChange website at www.icrxchange.com

On January 21, 2014, the Company will also participate at Jefferies 3rd Annual Winter Consumer Summit at the Ritz-Carlton Bachelor Gulch in Avon, Colorado.

About Noodles & Company

Founded in 1995, Noodles & Company is a fast-casual restaurant chain that serves classic noodle and pasta dishes from around the world with 380 locations system-wide in 29 states and the District of Columbia as of December 31, 2013. Known as Your World Kitchen, Noodles & Company's globally inspired menu consists of more than 25 fresh, customizable noodle bowls, salads, soups and sandwiches that are prepared quickly using quality ingredients. From healthy to indulgent, spicy to comforting, the menu provides favorites for everyone from kids to adults. Popular dishes include the spicy Indonesian Peanut Sauté, Med Salad with naturally raised pork and creamy Wisconsin Mac & Cheese.

Forward-Looking Statements

This press release contains a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words, and variations of words, such as "believe," "estimate," "anticipate," "expect," "intend," "may," "will," "would" and similar expressions are intended to identify our forward-looking statements. Examples of forward-looking statements include all matters that are not historical facts, such as statements regarding our preliminary financial results for the fourth quarter of 2013, including preliminary total revenue and preliminary comparable restaurant sales, and future restaurant development. By their nature, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the Company's forward-looking statements. These risks and uncertainties include any potential revisions or adjustments to our preliminary fourth quarter of 2013 financial results as the financial reporting process is completed and our ability to open new restaurants.  For additional information on these and other factors that could affect the Company's forward-looking statements, see the Company's risk factors, as they may be amended from time to time, set forth in its filings with the SEC, including the final prospectus filed December 9, 2013.  The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as may be required by applicable law or regulation.

Investor Relations Media Kristina Jorge (646) 277-1234

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 149

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 288

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 245

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 223

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Care Synergy and RCC Medical Equipment Launch New Partnership

Updated Category News Views 320

Care Synergy and RCC Medical Equipment Form Joint Venture In an exciting development for healthcare services, Care Synergy and RCC Medical Equipment Co. have announced their plans to create a strategic joint venture aimed at improving healthcare delivery in the Colorado Front Range region. This partnership will leverage the strengths of both organizations to provide...

Continue Reading
Revitalizing China's Tourism with High-Tech Cultural Experiences

Updated Category News Views 217

Revitalizing China's Tourism Through High-Tech Cultural Experiences China's tourism industry is undergoing an exciting transformation, fueled by the innovative use of advanced technology paired with its rich cultural heritage. A remarkable example is in Chongqing Municipality, where the city's skyline has become a vibrant showcase of cultural stories, highlighted by...

Continue Reading
Intriguing Insights into United States Steel Options Trades

Updated Category News Views 111

Analyzing Unusual Options Activity in United States Steel Recently, there's been notable market activity where investors with deep pockets are taking a more bearish stance on United States Steel (X). This trend is definitely something for retail traders to pay attention to, especially when navigating the complexities of the stock market. Today's options history unveiled...

Continue Reading
Mesoblast's Operational Highlights and Financial Insights Unveiled

Updated Category News Views 185

Mesoblast Limited's Webcast for Financial Results On a recent occasion, Mesoblast Limited (NASDAQ: MESO; ASX: MSB), a pioneer in allogeneic cellular medicine for inflammatory diseases, announced a webcast to delve into their operational achievements and financial metrics for the half year concluding December 31, 2024. Details of the Webcast Event The engaging webcast is...

Continue Reading
Investors of DXC Technology Prepare for Class Action Lawsuit

Updated Category News Views 77

Investors of DXC Technology Company Take Action In recent months, investors who purchased common stock from DXC Technology Company (NYSE: DXC) have been given a significant opportunity to participate in a class action lawsuit. This situation arises from allegations of securities fraud that are said to have affected many individuals who bought shares during specific key...

Continue Reading